The estimated Net Worth of Scott Biller is at least $14.9 Million dollars as of 11 June 2019. Scott Biller owns over 7,218 units of Agios Pharmaceuticals stock worth over $1,139,028 and over the last 6 years he sold AGIO stock worth over $10,699,357. In addition, he makes $3,098,050 as Chief Scientific Officer at Agios Pharmaceuticals.
Scott Biller AGIO stock SEC Form 4 insider trading
Scott has made over 69 trades of the Agios Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 7,218 units of AGIO stock worth $16,890 on 11 June 2019.
The largest trade he’s ever made was exercising 46,795 units of Agios Pharmaceuticals stock on 6 December 2017 worth over $81,423. On average, Scott trades about 7,121 units every 24 days since 2014. As of 11 June 2019 he still owns at least 33,729 units of Agios Pharmaceuticals stock.
You can see the complete history of Scott Biller stock trades at the bottom of the page.
Scott Biller biography
Dr. Scott Biller Ph.D., is no longer Chief Scientific Officer of Agios Pharmaceuticals, Inc., effective December 31, 2019. Dr. Biller joined Agios in September 2010 as chief scientific officer, with more than 25 years of drug discovery and development experience. From 2003 to September 2010, Dr. Biller was vice president and head of global discovery chemistry at the Novartis Institutes for Biomedical Research, an affiliate of publicly-traded biopharmaceutical company Novartis AG. Prior to that, Dr. Biller held the positions of vice president, pharmaceutical candidate optimization at the BMS Pharmaceutical Research Institute, a division of Bristol-Myers Squibb Company, or BMS, a global biopharmaceutical company, and executive director of drug discovery chemistry for the BMS research site in Lawrenceville, New Jersey. Among his other key leadership positions at BMS, Dr. Biller was the executive director of metabolic diseases chemistry. He contributed to the drug candidate pipelines at both BMS and Novartis AG, culminating in two medicines launched worldwide (Onglyza® for the treatment of Type 2 diabetes and Juxtapid® for familial hypercholesterolemia) and three additional drugs reaching phase 3 clinical development. Dr. Biller earned a S.B. in chemistry at MIT, a Ph.D. in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University focusing on natural product synthesis.
What is the salary of Scott Biller?
As the Chief Scientific Officer of Agios Pharmaceuticals, the total compensation of Scott Biller at Agios Pharmaceuticals is $3,098,050. There are 3 executives at Agios Pharmaceuticals getting paid more, with David Schenkein having the highest compensation of $8,199,320.
How old is Scott Biller?
Scott Biller is 63, he’s been the Chief Scientific Officer of Agios Pharmaceuticals since 2010. There are 2 older and 9 younger executives at Agios Pharmaceuticals. The oldest executive at Agios Pharmaceuticals, Inc. is David Scadden, 66, who is the Director.
What’s Scott Biller’s mailing address?
Scott’s mailing address filed with the SEC is 88 Sidney St, Cambridge, MA 02139, USA.
Insider trading at Agios Pharmaceuticals
Over the last 6 years, insiders at Agios Pharmaceuticals have traded over $74,010,240 worth of Agios Pharmaceuticals stock and bought 2,777,951 units worth $140,554,249 . The most active insider traders include Kevin P Starr, Robert Nelsen, and John Maraganore. On average, Agios Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $757,596. The most recent stock trade was executed by Scott Biller on 11 June 2019, trading 7,218 units of AGIO stock currently worth $16,890.
What does Agios Pharmaceuticals do?
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
What does Agios Pharmaceuticals’s logo look like?
Complete history of Scott Biller stock trades at Agios Pharmaceuticals
Agios Pharmaceuticals executives and stock owners
Agios Pharmaceuticals executives and other stock owners filed with the SEC include:
- David Schenkein, Executive Chairman of the Board
- Andrew Hirsch, Chief Financial Officer
- Christopher Bowden, Chief Medical Officer
- Scott Biller, Chief Scientific Officer
- John Maraganore, Independent Director
- Kaye Foster-Cheek, Independent Director
- Paul Clancy, Independent Director
- Maykin Ho, Independent Director
- David Scadden, Director
- Ian Clark, Independent Director
- Jacqualyn Fouse, Chief Executive Officer, Director
- Kendra Adams, Senior Director, Investor & Public Relations
- Darrin Miles, Senior Vice President, U.S. Commercial and Global Marketing
- Orlando Oliveira, Senior Vice President, General Manager, International
- Lewis Clayton Jr. Cantley, Director
- Carman Alenson, Principal Accounting Officer
- Douglas G. Cole, Director
- Steven L. Hoerter, Chief Commercial Officer
- Marc Tessier Lavigne, Director
- Robert Nelsen, Director
- European Investment Co Llc …,
- Corp /De/Celgene Switzerlan…,
- Ventures Fund 2007, L.P.Afe…,
- Venture Fund Vii Lparch Ven…,
- European Investment Co Llc …, 10% owner
- European Investment Co Llcc…,
- Rock Ventures Lp Third Rock…,
- Kevin P Starr, Director
- Glenn Goddard, Senior Vice President, Finance
- John Duncan Higgons, Chief Operating Officer
- Venture Fund Vii Lparch Ven…,
- Perry A Karsen, Director
